🔗 Share this article

Given that the United States continues making unprecedented changes to its vaccine recommendations, one figure has surfaced unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by questioning Covid vaccinations during the pandemic and has concentrated on alleged deaths following Covid vaccination in her brief tenure at the Food and Drug Administration.

Proposed Overhauls to Pediatric Vaccine Program

Health officials had intended to announce sweeping revisions to the childhood immunization program recently, aligning the US with Denmark’s immunization schedule, sources say – a substantial departure that would place the US out of alignment with many the international standard with little proof for improved outcomes. The announcement has been delayed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is set to address the audience at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this calendar year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific pediatric shot schedules in the US to become more in line with the Danish model, a society with nationalized medicine and a population about the population of Wisconsin’s.

In her initial comments, she has continued to focus on immunizations – traditionally the purview of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Doubts Over Expertise

Høeg has no obvious background in medication creation, regulation or management, which has been customary for former heads of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a scientific study. She lacks experience in leading a large organization. She is not an expert in industry regulation.”

Past directors of CBER would “understand legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who led CBER have had.”

This division has an enormous workload at the agency, Woodcock stated.

“Many people just focuses on the innovative therapies, but the off-patent medication office approves numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these have to be supervised,” Dr. Woodcock explained. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial management aspect to the role, which oversees in excess of 5,000 employees. “It is a huge leadership role, if you perform it correctly,” Woodcock added.

Agency Reaction and Contentious Policies

When asked about concerns about Høeg’s qualifications and whether this appointment signifies more teamwork among FDA leaders on immunizations, a representative responded that the “concerns are based on flawed presumptions”.

“Her resume matches the duties of her job,” the representative explained, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious rapid drug-approval program that reportedly troubled her predecessors. “How are these therapies being chosen for this voucher program? Who makes the decisions?” Dr. Howard asked. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration seems to be moving towards more relaxed rules of most medications, with the exception of vaccines.”

Documented Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a clearer, if concerning, track record, critics observe. She authored a research paper using unverified crowd-sourced reports to assess the incidence of myocarditis after COVID-19 vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “desired changes” for the current federal leadership featured changing rules for novel immunizations and ending “non-essential” vaccines, she stated after the election on a podcast. At the FDA, Dr. Høeg has reportedly proposed preventing young men from receiving Covid vaccinations.

“She is an all-around ideologue who commences with her preconceived notions and reverse-engineers to fit the data in a extremely disingenuous, fraudulent manner,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|